文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

儿童及青少年癌症DNA损伤反应通路抑制剂药物研发儿科策略论坛:ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
PubMed 文献 · Eur J Cancer · 2023-06-21

该论坛探讨DNA损伤反应抑制剂在儿童癌症中的治疗角色,强调需优先排序与整体策略。PARP抑制剂在儿童肿瘤中BRCA1/2突变少见,需特定应答假设;不推荐相同机制PARP抑制剂重复单药试验。CHK1抑制剂在促结缔组织增生性小圆细胞肿瘤中显示活性,获取CHK1抑制剂用于儿科临床试验为高度优先。

要点

  • 不推荐相同作用机制的PARP抑制剂在儿童中重复开展单药试验。
  • CHK1抑制剂在促结缔组织增生性小圆细胞肿瘤中显示活性,获取用于儿科临床试验为高度优先。
  • 评估这些抑制剂的三要素为创新试验设计、生物标志物选择及合理联合治疗。

核心结论

  • DNA损伤反应抑制剂在儿童癌症中具有潜在重要治疗作用,但其最佳使用包括患者选择和联合策略仍未知。
  • 需要优先排序和整体协调策略,以解决不同机制药物数量与可入组早期试验的有限儿科患者之间的不平衡。
  • 不推荐相同作用机制的PARP抑制剂重复开展单药试验。

研究设计与样本

  • 儿科策略论坛,由ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与。

主要发现

  • PARP抑制剂靶向同源重组缺陷肿瘤主要用于成人BRCA1/2突变癌症,但BRCA1/2突变在儿童肿瘤中不常见,因此需要特定应答假设。
  • 与靶向放疗、ATR抑制剂或携带DNA拓扑异构酶I抑制剂弹头的抗体药物偶联物联合值得评估。
  • PARP1特异性抑制剂及中枢神经系统穿透性良好的PARP抑制剂也值得评估。
  • ATR、ATM、DNA-PK、CHK1、WEE1、DNA聚合酶θ和PKMYT1抑制剂在儿科开发中处于早期阶段。
  • CHK1抑制剂在促结缔组织增生性小圆细胞肿瘤中已显示活性,并可能在神经母细胞瘤和尤文肉瘤等其他儿科恶性肿瘤治疗中发挥作用。

关键数值与推荐

  • 评估这些抑制剂在儿童中的三个关键要素为:创新试验设计(由明确假设驱动,意图通过详细回顾性分子分析进一步研究应答者与非应答者以产生修订或新假设)、生物标志物选择及合理联合治疗(受重叠毒性限制)。
  • 将建立学术界/产业界相关生物标志物共识,并召开聚焦ATR抑制剂的会议作为概念验证。

临床怎么用

  • 研究者应合作,从过去吸取教训并应用于未来研究。
  • 计划应基于相关生物学,重点在临床前和临床环境中同时并行研究,并采用整体整合与协作策略。

局限性

  • DNA损伤反应抑制剂的最佳使用包括患者选择和联合策略仍未知。
  • 不同机制药物数量与可入组早期试验的有限儿科患者之间存在不平衡。
  • 合理联合治疗受重叠毒性限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance between the number of drugs with diverse mechanisms of action and the limited number of paediatric patients available to be enrolled in early-phase trials, so prioritisation and a strategy are essential. While PARP inhibitors targeting homologous recombination-deficient tumours have been used primarily in the treatment of adult cancers with BRCA1/2 mutations, BRCA1/2 mutations occur infrequently in childhood tumours, and therefore, a specific response hypothesis is required. Combinations with targeted radiotherapy, ATR inhibitors, or antibody drug conjugates with DNA topoisomerase I inhibitor-related warheads warrant evaluation. Additional monotherapy trials of PARP inhibitors with the same mechanism of action are not recommended. PARP1-specific inhibitors and PARP inhibitors with very good central nervous system penetration also deserve evaluation. ATR, ATM, DNA-PK, CHK1, WEE1, DNA polymerase theta and PKMYT1 inhibitors are early in paediatric development. There should be an overall coordinated strategy for their development. Therefore, an academia/industry consensus of the relevant biomarkers will be established and a focused meeting on ATR inhibitors (as proof of principle) held. CHK1 inhibitors have demonstrated activity in desmoplastic small round cell tumours and have a potential role in the treatment of other paediatric malignancies, such as neuroblastoma and Ewing sarcoma. Access to CHK1 inhibitors for paediatric clinical trials is a high priority. The three key elements in evaluating these inhibitors in children are (1) innovative trial design (design driven by a clear hypothesis with the intent to further investigate responders and non-responders with detailed retrospective molecular analyses to generate a revised or new hypothesis); (2) biomarker selection and (3) rational combination therapy, which is limited by overlapping toxicity. To maximally benefit children with cancer, investigators should work collaboratively to learn the lessons from the past and apply them to future studies. Plans should be based on the relevant biology, with a focus on simultaneous and parallel research in preclinical and clinical settings, and an overall integrated and collaborative strategy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pearson ADJ, Federico S, Gatz SA, et al. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2023. PMID: 37441939. doi:10.1016/j.ejca.2023.112950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。